Zenith Epigenetics Strengthens its Management Team with Key Appointments

CALGARY, Sept. 8, 2014 /CNW/ - Zenith Epigenetics Corp. ("Zenith" or the "Company") today announced that it has appointed Joy Zhu, MD, PhD, as Chief Medical Officer, Sanjay Lakhotia, PhD, as Chief Business Officer, and Michael Yakes, PhD, as Vice President Drug Discovery and Exploratory Development.

Dr. Zhu joins Zenith at a pivotal time, just ahead of the first-in-human oncology clinical trials investigating Zenith's proprietary BET inhibitor, ZEN-3365. Dr. Zhu has over 20 years of oncology clinical development experience and has led the design and execution of multiple clinical trials including those resulting in the approval of successful products such as SUTENTÒ and XGEVA. Prior to joining Zenith, Dr. Zhu held leadership positions at SUGEN/Pfizer, S*BIO Pte Ltd, Amgen, JNJ, and Novartis. Most recently, Dr. Zhu led oncology clinical development at Halozyme Therapeutics.

Dr. Lakhotia brings significant business, operational, and product development expertise to Zenith, with more than two decades of experience at innovative pharmaceutical and biotech companies, including Wyeth Pharmaceuticals, MedImmune, Onyx Pharmaceuticals, Portola Pharmaceuticals, and Pathway Therapeutics. He has contributed to the business development and product development efforts for significant products such as Prevnar, Nexavar, and FluMist.

Dr. Yakes has over 15 years of experience in the discovery and development of novel cancer therapeutics. Prior to joining Zenith, Dr. Yakes held the position of Senior Director, Translational Biology at Cleave Biosciences. Prior to Cleave Biosciences, he held positions of increasing responsibility at Exelixis, making major contributions to the preclinical characterization and IND/NDA filings for COMETRIQ (cabozantanib).

Dr. Julie Cherrington, President and CEO of Zenith, remarked, "I am very excited to welcome Joy, Sanjay and Mike to Zenith's management team. We have a great foundation to develop a best in class BET inhibitor for the treatment of hematological malignancies and solid tumors in select patient populations. This is a pivotal step in building a leading epigenetics company".

About Zenith

Zenith Epigenetics Corp. is a clinical stage biotechnology company focused on the discovery and development of novel therapeutics by applying its proprietary epigenetics platform. Zenith's bromodomain (BET) inhibitors are being advanced in several oncology indications and have the potential to impact multiple additional diseases as well.

SOURCE: Zenith Epigenetics Corp.

For further information:

Calgary Office
300, 4820 Richard Road SW
Calgary, AB, T3E 6L1

San Francisco Office
Suite 4010, 44 Montgomery Street
San Francisco, CA 94104

Telephone: (587) 390-7865
Email: info@zenithepigenetics.com   

Organization Profile

Zenith Epigenetics Corp.

More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890